Source: MS Trust
The next step in the approval process is for the European Commission to grant a licence for cladribine, taking into consideration the EMA’s recommendation. Cladribine will then have to be appraised by NICE and the SMC to determine availability in the UK.
In anticipation of the granting of a licence, NICE have already started the appraisal process and a decision is expected to be published in February 2018. The MS Trust is contributing to the appraisal. If NICE approves the use of cladribine, it could be available on the NHS from June 2018. Read on.